Research Article
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients
Table 1
Comparison of clinical presentations in COVID-19 patients on two different combination therapies.
| | Duration (days) | Lopinavir/ritonavir
(%) | Atazanavir/ritonavir
(%) | value |
| | Febrile | 0-3 | 53 (50) | 53 (50) | 1.00 | | 3-5 | 1 (50) | 1 (50) | | Admission | 3-5 | 0 (0) | 1 (100) | 0.479 | | 5-7 | 6 (42.9) | 8 (57.1) | | 7-9 | 23 (53.5) | 20 (46.5) | | 9-11 | 21 (56.8) | 16 (43.2) | | 11-13 | 4 (33.3) | 8 (66.7) | | >14 | 0 (0) | 1 (100) | | Hypoxic | 0-3 | 23 (43.4) | 30 (56.6) | 0.343 | | 3-5 | 18 (62.1) | 11 (37.9) | | 5-7 | 1 (20) | 4 (80) | | 7-9 | 1 (33.3) | 2 (66.7) | | 9-11 | 8 (61.5) | 5 (38.5) | | 11-13 | 3 (60) | 2 (40) | | Myalgia | 0-5 | 48 (52.2) | 44 (47.8) | 0.412 | | 5-10 | 6 (40) | 9 (60) | | >10 | 0 (0) | 1 (100) | | Cough | 0-5 | 39 (47.6) | 43 (52.4) | 0.334 | | 5-10 | 15 (60) | 10 (40) | | >10 | 0 (0) | 1 (100) | | Dyspnea | 0-5 | 47 (52.8) | 42 (47.2) | 0.417 | | 5-10 | 6 (35.3) | 11 (64.7) | | >10 | 1 (50) | 1 (50) | | Headache | 0-5 | 51 (49.5) | 52 (50.5) | 0.647 | | 5-10 | 3 (60) | 2 (40) | | Anorexia | 0-5 | 51 (50.5) | 50 (49.5) | 0.90 | | 5-10 | 2 (40) | 3 (60) | | Nausea | 0-5 | 53 (50) | 53 (50) | 1.00 | | 5-10 | 1 (50) | 1 (50) | | Diarrhea | 0-5 | 53 (49.5) | 54 (50.5) | 0.315 | | 5-10 | 1 (100) | 0 (0) | | Sore throat | 0-5 | 53 (50) | 53 (50) | 1.00 | | 5-10 | 1 (50) | 1 (50) | | Abdominal pain | 0-5 | 3 (42.9) | 4 (57.1) | 0.696 | | Skin rash | 0-5 | 2 (22.2) | 7 (77.8) | 0.082 |
|
|
